Joseph E Burgents
Overview
Explore the profile of Joseph E Burgents including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grunwald V, McKay R, Buchler T, Eto M, Park S, Takagi T, et al.
Int J Cancer
. 2024 Dec;
156(7):1326-1335.
PMID: 39739622
Lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib in treatment of advanced renal cell carcinoma (aRCC) in the phase 3 CLEAR study. We report results of an exploratory post hoc...
2.
Choueiri T, Tomczak P, Park S, Venugopal B, Ferguson T, Symeonides S, et al.
N Engl J Med
. 2024 Apr;
390(15):1359-1371.
PMID: 38631003
Background: Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results regarding overall...
3.
Grunwald V, Powles T, Eto M, Kopyltsov E, Rha S, Porta C, et al.
Front Oncol
. 2024 Mar;
13:1343027.
PMID: 38495081
[This corrects the article DOI: 10.3389/fonc.2023.1223282.].
4.
Grunwald V, Powles T, Eto M, Kopyltsov E, Rha S, Porta C, et al.
Front Oncol
. 2023 Sep;
13:1223282.
PMID: 37664025
Introduction: The phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features including...
5.
Powles T, Burgents J, Xu L, Choueiri T
Lancet Oncol
. 2023 Jan;
24(1):e1-e2.
PMID: 36603921
No abstract available.
6.
Powles T, Tomczak P, Park S, Venugopal B, Ferguson T, Symeonides S, et al.
Lancet Oncol
. 2022 Sep;
23(9):1133-1144.
PMID: 36055304
Background: The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared with placebo after surgery in patients with clear cell renal cell carcinoma at...
7.
van Deventer H, Burgents J, Wu Q, Woodford R, Brickey W, Allen I, et al.
Cancer Res
. 2010 Dec;
70(24):10161-9.
PMID: 21159638
The inflammasome is a proteolysis complex that generates the active forms of the proinflammatory cytokines interleukin (IL)-1β and IL-18. Inflammasome activation is mediated by NLR proteins that respond to microbial...
8.
Burgents J, Moran T, West M, Davis N, Johnston R, Serody J
J Immunother
. 2010 May;
33(5):482-91.
PMID: 20463599
We earlier showed that therapeutic vaccination of FVB/N mice with alphaviral replicon particles expressing rat neuET-VRP induced regression of established neu-expressing tumors. In this study, we evaluated the efficacy of...
9.
Coghill J, Carlson M, Panoskaltsis-Mortari A, West M, Burgents J, Blazar B, et al.
Blood
. 2010 Feb;
115(23):4914-22.
PMID: 20185583
CC-chemokine receptor 7 (CCR7) is expressed on the surface of naive T cells, and plays a critical role in their movement into secondary lymphoid tissue. Here, we show that murine...
10.
Moran T, Burgents J, Long B, Ferrer I, Jaffee E, Tisch R, et al.
Vaccine
. 2007 Aug;
25(36):6604-12.
PMID: 17675184
While dendritic cell (DC) vaccines can protect hosts from tumor challenge, their ability to effectively inhibit the growth of established tumors remains indeterminate. Previously, we have shown that human DCs...